iRS-AD
Alzheimer's Disease Diagnosis
Research/DevelopmentActive
Key Facts
About BetaSense
BetaSense is an early-stage diagnostics company developing a proprietary structural biomarker detection platform called iRS. The technology uses infrared spectroscopy to identify misfolded proteins in biofluids like serum and CSF, demonstrating high diagnostic accuracy (AUC >0.93) for Parkinson's disease. Founded in 2025, the company operates as a CRO lab, collaborates with pharmaceutical partners, and is positioning its platform for clinical diagnostics and drug development support. Its goal is to shift neurodegenerative disease management to pre-symptomatic stages.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Diagnosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Afina Retinal Imaging | NeuroVision Imaging | Validation/Development |
| Aβ1-40/Aβ1-42/Tau IMR Reagents | MagQu | Commercial |
| Alzheimer's Biomarker | Aelan Cell Technologies | Test Stage |
| Oligomer Diagnostic Biomarkers | Abyssinia Biologics | Preclinical/Research |
| ABtest-Service | Araclon Biotech | Commercial |
| AlzTEST® | Neuron Biopharma | Not Specified |